SCHEMBL25262011

SCHEMBL25262011

Nc1nc2ccc(Nc3ccncc3)cc2s1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.68
KDM4E B2RXH2 2/20 0.68
MEN1 O00255 1/20 0.68
PIK3CD O00329 5/20 0.60
PIK3CA P42336 4/20 0.60
PIK3CG P48736 4/20 0.60
PI4KA P42356 4/20 0.60
PI4KB Q9UBF8 4/20 0.60
PIK3CB P42338 3/20 0.60
PIP5K1C O60331 3/20 0.60
RAB9A P51151 3/20 0.56
SYK P43405 1/20 0.53
MAPT P10636 2/20 0.50
HTT P42858 2/20 0.50
EPHX2 P34913 2/20 0.50
AXL P30530 1/20 0.50
GFER P55789 1/20 0.50
GAA P10253 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
RAD52 P43351 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31114573 1.00 KMT2A (0.68) KMT2AKDM4EMEN1PIK3CDPIK3CA
SCHEMBL11699532 0.86 PI4KA (0.59) KMT2AKDM4EMEN1PIK3CDPIK3CA
SCHEMBL30451155 0.82 SYK (0.55) KMT2AKDM4EMEN1PIK3CDPIK3CA
SCHEMBL25303974 0.82 SYK (0.55) KMT2AKDM4EMEN1PIK3CDPIK3CA
SCHEMBL25256944 0.79 PIK3CD (0.53) KMT2AKDM4EMEN1PIK3CDPIK3CA
SCHEMBL25304126 0.79 SYK (0.55) KMT2AKDM4EMEN1PIK3CDPIK3CA
SCHEMBL31114585 0.79 PIK3CD (0.53) KMT2AKDM4EMEN1PIK3CDPIK3CA
SCHEMBL30451455 0.79 SYK (0.55) KMT2AKDM4EMEN1PIK3CDPIK3CA
SCHEMBL20247001 0.77 RAB9A (0.61) KMT2AKDM4EPIK3CDPIK3CAPIK3CG
SCHEMBL25303756 0.77 SYK (0.65) KMT2AKDM4EMEN1PIK3CDPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250382273-A1 BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS INST NAT SANTE RECH MED (FR) 2025-12-18 US disclosed
EP-4460500-A1 BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM (FR) 2024-11-13 EP disclosed
WO-2023131649-A1 BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2023-07-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250382273-A1 BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS BBOX1, NDUFB6, NDUFB5 KMT2A 3680/4885KDM4E 3247/4885MEN1 4191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.